Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7321 to 7335 of 7675 results

  1. Diabetes in adults (QS6)

    This quality standard is updated and replaced by the quality standards on type 1 diabetes in adults (QS208) and type 2 diabetes in adults (QS209).

  2. Glaucoma in adults (QS7)

    This quality standard has been updated and replaced by NICE quality standard 180.

  3. Therapeutic hypothermia following cardiac arrest (IPG386)

    This guidance has been updated and replaced by NICE interventional procedures guidance 782.

  4. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

    This evidence summary has been updated and replaced by NICE guideline 115.

  5. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

  6. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development [GID-TA10935] Expected publication date: TBC

  7. Sepsis (QS161)

    February 2024: We have temporarily withdrawn this quality standard due to ongoing updates to the NICE guideline on sepsis, which underpins the quality statements. See the guidance in development page and guideline in development page for progress on these updates.

    For any queries, please contact qualitystandards@nice.org.uk

  8. Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

    In development [GID-TA10800] Expected publication date: TBC

  9. High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

    Discontinued [GID-IPG10142]

  10. COVID-19 rapid guideline: severe asthma (NG166)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.

  11. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development [GID-TA11070] Expected publication date: TBC

  12. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

  13. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued [GID-IP2806]